BIONIK Laboratories Corp. (OTCMKTS:BNKL) announced on March 30, 2022, about participating in the American Occupational Therapy Association (AOTA) Conference in San Antonio, Texas from March 31 –April 3, 2022. The focus will be around its InMotion technology, on display at booth 801. The AOTA Conference & Expo brings industry workers and professionals together to explore the latest updates on practice, professional issues, and trends.
Market Reaction
On Wednesday, BNKL stock ended flat at $0.3750 with 2 shares, compared to its average volume of 110 shares. The stock moved within a range of $0.3750 – 0.3750 after opening trade at $0.3750.
The robotics company is actively engaged in providing rehabilitation and assistive technology solutions to stroke survivors and others with neurological and mobility challenges from hospital to home. The InMotion robotics ability delivers intensive therapy to patients for regaining motor function after a stroke and other neurological conditions or injuries.
The game-changing InMotion ARM is an evidence-based neuro-rehabilitation technology that provides patients with real-time Assistance-as-Needed. It quietly keeps tabs on patients’ movements during therapy, while gently assisting them to complete several motor therapy activities. The objective is to improve motor control of the arm and hand by increasing strength, range of motion and coordination, and assisting with the provision of efficient, effective, and intensive sensorimotor therapy.
The InMotion robots were developed according to the principles of motor learning and neuro-plasticity, using AI and measuring the position, the speed and the acceleration of the upper limb 200 times a second.
Key Quote
“We look forward to attending AOTA as their mission to advance occupational therapy practices, education and research aligns with BIONIK’s values. Our presence at AOTA gives us the opportunity to connect with our core audience, Occupational Therapists, and showcase how our devices, like the InMotion® ARM and ARM/HAND can help achieve the overall goal of improving a patient’s quality of life,” said Richard Russo, Jr., Chief Financial Officer and Interim Chief Executive Office of BIONIK. “Our attendance at this event allows us to share the benefits of our InMotion® devices as well as the ongoing training, education and support that we provide for patient results.”
Traders Review
BNKL stock is trading below the 20-Day and 50-Day Moving averages of $0.45 and $0.71 respectively. Moreover, the stock is trading below the 200-Day moving average of $1.34.
